First modification: 14/06/2020 – 11:22
–
France, Germany, Italy and the Netherlands signed a contract with the laboratory AstraZeneca to acquire up to 400 million doses of the vaccine against the coronavirus, currently in the stage of experimentation by the University of Oxford, England. The address of the laboratory claims that the vaccine could be available before the end of the year and vowed to get benefits and sell it at the cost of production.
The race to find the vaccine to help combat the Covid-19 and save millions of lives have entered a new stage. France, Germany, Italy and the Netherlands reported this Saturday have come to an agreement with the laboratory AstraZeneca to ensure the provision of 400 million doses of the vaccine that develops in the experimental phase and that could be ready before the end of the year.
The announcement came at a time in which the coronavirus has infected more than 7.4 million people in the world and causing the death of more than 417 000. The vaccine they are working on that lab and the University of Oxford is one of the 10 that are in various stages of clinical testing in the world. The difference is that in this case the british authorities of regulation they agreed to give their approval for the launch of phase three of the tests, whereas the results so far are encouraging.
According to the statement released by the laboratory, AstraZeneca “will launch a supply chain located in Europe.” The doses must be “distributed to all member states of the European Union who want to participate, depending on the size of its population”, said for his part the German minister of health. “The access to the vaccine will be an essential step to ensure the protection of our citizens,” said for his part the French minister of health.
It is not known, the figure advanced by the four pa1ses to ensure the provisioning of the promised vaccine.
Last Friday, the European Commission insisted that the 27 member states of the European Union on the need to group all of your efforts to ensure a privileged access to a future vaccine. This is due to the signing of contracts for the advance purchase for which the Commission is willing to use 2 to 400 million euros. In mid-may, the lab French Sanofi, triggered a huge controversy after discovering that in the event that discovered the vaccine coronavirus would give the priority to the population of the united States.
AstraZeneca is currently testing in Great Britain and in Brazil, the latter become the main focus of the pandemic. The laboratory has other contracts of global manufacturing, in particular with the u.s. government and with two funds that supports Bill Gates.
– .
